Survival Similar for Black, White Prostate Cancer Patients in Clinical Trial Setting

FRIDAY, Aug. 4, 2023 -- For metastatic castration-sensitive prostate cancer (mCSPC), overall survival and progression-free survival are similar for Black and White patients receiving first- or second-generation androgen receptor pathway inhibitors...